New Amsterdam sees success in Phase III cardiovascular disease trial [Yahoo! Finance]
Silence Therapeutics Plc - American Depository Share (SLN)
Company Research
Source: Yahoo! Finance
The combination treatment is designed for patients living with heterozygous familial hypercholesterolemia (HeFH) or atherosclerotic cardiovascular disease (ASCVD). The Netherlands-based company has been working to develop oral, non-statin medicines for patients at risk of cardiovascular disease (CVD) with elevated low-density lipoprotein cholesterol (LDL-C), for whom existing therapies are not working. Results from the TANDEM trial (NCT06005597) will be used to support regulatory and approval filings for the 10 mg obicetrapib and 10 mg ezetimibe fixed-dose combination treatment for patients already using maximally tolerated lipid-lowering therapy that has yet to see results. Results found that the trial met both of its co-primary endpoints, measured as a change in baseline LDL-C, compared with the monotherapy arm after 84 days and obicetrapib 10 mg compared to placebo after the same period. The obicetrapib-ezetimibe fixed dose combination achieved an LS mean reduction of 48.6%.
Show less
Read more
Impact Snapshot
Event Time:
SLN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SLN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SLN alerts
High impacting Silence Therapeutics Plc - American Depository Share news events
Weekly update
A roundup of the hottest topics
SLN
News
- SLN Stock Down Despite Cholesterol Drug Lowering Lipoprotein Levels [Yahoo! Finance]Yahoo! Finance
- Silence Therapeutics plc (NASDAQ: SLN) had its "outperform" rating re-affirmed by analysts at William Blair.MarketBeat
- Silence Therapeutics Presents Late-Breaking Phase 2 Zerlasiran Data at 2024 American Heart Association (AHA) Annual Meeting [Yahoo! Finance]Yahoo! Finance
- Silence Therapeutics Presents Late-Breaking Phase 2 Zerlasiran Data at 2024 American Heart Association (AHA) Annual MeetingBusiness Wire
- Silence Therapeutics plc (NASDAQ: SLN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $75.00 price target on the stock.MarketBeat
SLN
Sec Filings
- 11/18/24 - Form 6-K
- 11/14/24 - Form SC
- 11/14/24 - Form SC
- SLN's page on the SEC website